Cargando…

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant cancers. The treatment of HNSCC remains challenging despite recent progress in targeted therapies and immunotherapy. Research on predictive biomarkers in clinical settings is urgently needed. METHODS: Next-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Shengjin, Zhang, Lin, Wang, Chong, Yao, Yanli, Jiang, Wen, Ye, Lulu, Li, Jiang, Wu, Sicheng, Sun, Debin, Gong, Xiaoli, Li, Rongrong, Zhu, Guopei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965897/ https://www.ncbi.nlm.nih.gov/pubmed/35371031 http://dx.doi.org/10.3389/fimmu.2022.813732

Ejemplares similares

Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial
por: Jiang, Wen, et al.
Publicado: (2023)

Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study
por: Ye, Lulu, et al.
Publicado: (2023)

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
por: Xu, Xuanli, et al.
Publicado: (2021)

Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
por: Zhu, Guopei, et al.
Publicado: (2021)

The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
por: Dou, Shengjin, et al.
Publicado: (2021)

Long‐term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study
por: Dou, Shengjin, et al.
Publicado: (2020)

A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors: Preliminary results
por: Li, Rongrong, et al.
Publicado: (2018)

Tailored multimodality therapy guided by a two-step decision making process for head-and-neck cancer of unknown primary
por: Dou, Shengjin, et al.
Publicado: (2016)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

3q26 Amplifications in Cervical Squamous Carcinomas
por: Voutsadakis, Ioannis A.
Publicado: (2021)

EGFR Mutations in Head and Neck Squamous Cell Carcinoma
por: Nair, Sindhu, et al.
Publicado: (2022)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Study of EGFR mutations in head and neck squamous cell carcinomas
por: Kaur, Gurpreet, et al.
Publicado: (2021)

Longitudinal Body Composition Changes and the Importance of Fat-Free Mass Index in Locally Advanced Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy
por: Ding, Huiping, et al.
Publicado: (2018)

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
por: Fasano, Morena, et al.
Publicado: (2021)

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
por: Schuler, Patrick J, et al.
Publicado: (2011)

The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy
por: Jiang, Chao, et al.
Publicado: (2022)

Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma
por: Zhang, Jian, et al.
Publicado: (2020)

Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma
por: Paxton, Christian N., et al.
Publicado: (2015)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
por: Barzegar, Mansoureh, et al.
Publicado: (2017)

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
por: Baba, Yuh, et al.
Publicado: (2012)

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
por: Bossi, Paolo, et al.
Publicado: (2016)

EGFR modulates complement activation in head and neck squamous cell carcinoma
por: Abu-Humaidan, Anas H. A., et al.
Publicado: (2020)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)
por: Huang, Yingying, et al.
Publicado: (2023)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck.
por: Ishitoya, J., et al.
Publicado: (1989)

Identification of Therapeutic and Prognostic Biomarkers of Lamin C (LAMC) Family Members in Head and Neck Squamous Cell Carcinoma
por: Jiang, Pan, et al.
Publicado: (2020)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2016)

Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
por: Yu, Chenhang, et al.
Publicado: (2022)

Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
por: Zhang, Yueming, et al.
Publicado: (2020)

Distinctive Expression and Amplification of Genes at 11q13 in Relation to HPV Status with Impact on Survival in Head and Neck Cancer Patients
por: Hermida-Prado, Francisco, et al.
Publicado: (2018)

Amplification of the EGFR and CCND1 Are Coordinated and Play Important Roles in the Progression of Oral Squamous Cell Carcinomas
por: Chien, Huei-Tzu, et al.
Publicado: (2019)

Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
por: Liu, Xingyu, et al.
Publicado: (2020)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_25t2tttcocmplsivm54fth35bg